Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Augmentation of local antitumor immunity in the liver by tumor vaccine modified to secrete murine interleukin 12

Gene Therapy volume 6, pages 1120–1127 (1999)Cite this article

Abstract

Minimal residual lesions have been a major problem in surgical management of cancer. We transfected M5076 with murine IL-12 gene by a retroviral vector, established a stable transfectant secreting IL-12 and investigated its antitumor effects on a spontaneous liver metastasis murine model of M5076 reticulum cell sarcoma. Subcutaneous vaccination of the irradiated transfectant into the remote skin following the amputation of the tumor-bearing limb improved survival when compared with the vaccination of irradiated parental cells (control). Cytotoxic activities against parental M5076 were significantly stronger in the hepatic lymphocytes from the mice vaccinated with the IL-12 transfectant than those from the control. IFN-γ production of hepatic lymphocytes when they were cocultured with the parental cells was significantly augmented in mice vaccinated with the IL-12 transfectant compared with the control. On the other hand, both cytotoxic activity and IFN-γ production of spleen cells in the M5076-vaccinated and transfectant-vaccinated mice were at similar levels. Immunophenotypic analysis revealed the selective increase of CD3+NK1+ population in the liver from the transfectant-vaccinated mice. These results suggest that tumor vaccines genetically modified to secrete IL-12 continuously at a relatively low level preferentially augment local antitumor activity in the liver rather than systemic immune responses. This strategy warrants further investigation as an adjuvant modality in the management of postoperative residual tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Ross HM et al. Adenoviral thymidine kinase prodrug gene therapy inhibits sarcoma growth in vivo J Surg Res 1997 70: 7–11

    Article  CAS  Google Scholar 

  2. Prehn RT . Two competing influences that may explain concomitant tumor resistance Cancer Res 1993 53: 3266–3269

    CAS  Google Scholar 

  3. Gorelik E, Segal S, Feldman M . On the mechanism of tumor ‘concomitant immunity’ Int J Cancer 1981 27: 847–856

    Article  CAS  Google Scholar 

  4. Fisher B, Gunduz N, Saffer EA . Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases Cancer Res 1983 43: 1488–1492

    CAS  Google Scholar 

  5. Nomi S, Pellis NR, Kahan BD . Retardation of postsurgical metastases with the use of extracted tumor-specific transplantation antigens and cyclophosphamide J Natl Cancer Inst 1984 73: 943–950

    CAS  Google Scholar 

  6. Tada T et al. Transforming growth factor-β-induced inhibition of T cell function: susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state J Immunol 1991 146: 1077–1082

    CAS  Google Scholar 

  7. Yamamoto N et al. Regulatory mechanisms for production of IFN-γ and TNF by antitumor T cells or macrophages in the tumor-bearing state J Immunol 1995 154: 2281–2290

    CAS  Google Scholar 

  8. Chen DS et al. Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice Hum Gene Ther 1997 8: 1667–1674

    Article  CAS  Google Scholar 

  9. Colombo MP, Forni G . Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994 15: 48–51

    Article  CAS  Google Scholar 

  10. Jaffee EM, Pardoll DM . Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines Methods 1997 12: 143–153

    Article  CAS  Google Scholar 

  11. Colombo MP, Rodolfo M . Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? Cancer Immunol Immunother 1995 41: 265–270

    Article  CAS  Google Scholar 

  12. Pardoll DM . Cancer vaccines: a road map for the next decade Curr Opin Immunol 1996 8: 619–621

    Article  CAS  Google Scholar 

  13. Vagliani M et al. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells Cancer Res 1996 56: 467–470

    CAS  Google Scholar 

  14. Zitvogel L et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors Eur J Immunol 1996 26: 1335–1341

    Article  CAS  Google Scholar 

  15. Lode HN et al. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma Proc Natl Acad Sci USA 1998 95: 2475–2480

    Article  CAS  Google Scholar 

  16. Kobayashi M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes J Exp Med 1989 170: 827–845

    Article  CAS  Google Scholar 

  17. Stern AS et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells Proc Natl Acad Sci USA 1990 87: 6808–6812

    Article  CAS  Google Scholar 

  18. Gately MK et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor) J Immunol 1991 147: 874–882

    CAS  Google Scholar 

  19. Wolf SF et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells J Immunol 1991 146: 3074–3081

    CAS  Google Scholar 

  20. Schoenhaut DS et al. Cloning and expression of murine IL-12 J Immunol 1992 148: 3433–3440

    CAS  Google Scholar 

  21. Gately MK et al. Administration of recombinant IL-12 to normal mice enhances the cytolytic lymphocyte activity and induces production of IFN-γ in vivo Intern Immunol 1994 6: 157–167

    Article  CAS  Google Scholar 

  22. Brunda MJ et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors J Exp Med 1993 178: 1223–1230

    Article  CAS  Google Scholar 

  23. Hashimoto W et al. Cytotoxic NK1.1 Ag+ αβ T cells with intermediate TCR induced in the liver of mice by IL-12 J Immunol 1995 154: 4333–4340

    CAS  Google Scholar 

  24. Hart IR, Talmadge JE, Fidler IJ . Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth Cancer Res 1981 41: 1281–1287

    CAS  Google Scholar 

  25. Acerbis G et al. Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosurea on spontaneous metastases of a non-immunogenic murine tumour Cancer Immunol Immunother 1992 34: 383–388

    Article  CAS  Google Scholar 

  26. Takeda K et al. Liver NK1.1+ CD4+ αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis J Immunol 1996 156: 3366–3373

    CAS  Google Scholar 

  27. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 1993 90: 3539–3543

    Article  CAS  Google Scholar 

  28. Porgador A et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells Cancer Res 1992 52: 3679–3686

    CAS  Google Scholar 

  29. Colombo MP et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo J Exp Med 1991 173: 889–897

    Article  CAS  Google Scholar 

  30. Rodolfo M et al. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens J Immunol 1996 157: 5536–5542

    CAS  Google Scholar 

  31. Hall SS . IL-12 at the crossroads Science 1995 268: 1432–1434

    Article  CAS  Google Scholar 

  32. Marshall E . Cancer trial of interleukin-12 halted Science 1995 268: 1555

    Article  Google Scholar 

  33. Cui J et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors Science 1997 278: 1623–1626

    Article  CAS  Google Scholar 

  34. Anzai R et al. Interleukin-12 induces cytotoxic NK1+ αβ T cells in the lungs of euthymic and athymic mice Immunology 1996 88: 82–89

    Article  CAS  Google Scholar 

  35. Nastala CL et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production J Immunol 1994 153: 1697–1706

    CAS  Google Scholar 

  36. Martinotti A et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes Eur J Immunol 1995 25: 137–146

    Article  CAS  Google Scholar 

  37. Chen SH et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo Proc Natl Acad Sci USA 1995 92: 2577–2581

    Article  CAS  Google Scholar 

  38. Russell DW, Miller AD, Alexander IE . Adeno-associated virus vectors preferentially transduce cells in S phase Proc Natl Acad Sci USA 1994 91: 8915–8919

    Article  CAS  Google Scholar 

  39. Podsakoff G, Wong KK Jr, Chatterjee S . Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors J Virol 1994 68: 5656–5666

    CAS  PubMed Central  Google Scholar 

  40. Angiolillo AL et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo J Exp Med 1995 182: 155–162

    Article  CAS  Google Scholar 

  41. Tannenbaum CS et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12 J Immunol 1996 156: 693–699

    CAS  Google Scholar 

  42. Nanni P et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases Cancer Res 1998 58: 1225–1230

    CAS  Google Scholar 

  43. Tahara H et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector J Immunol 1995 154: 6466–6474

    CAS  Google Scholar 

  44. Tahara H et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo Cancer Res 1994 54: 182–189

    CAS  Google Scholar 

  45. Watanabe H et al. Details of an isolation method for hepatic lymphocytes in mice J Immunol Meth 1992 146: 145–154

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kawaramachi Hirokoji, Kamigyo-ku, Kyoto, 602–8566, Japan

    N Fuji, H Fujiwara, Y Ueda, F Taniguchi, T Yoshimura & T Oka

  2. First Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kawaramachi Hirokoji, Kamigyo-ku, Kyoto, 602–8566, Japan

    H Yamagishi

Authors
  1. N Fuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Yamagishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fuji, N., Fujiwara, H., Ueda, Y. et al. Augmentation of local antitumor immunity in the liver by tumor vaccine modified to secrete murine interleukin 12. Gene Ther 6, 1120–1127 (1999). https://doi.org/10.1038/sj.gt.3300916

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3300916

Keywords

This article is cited by

Search

Advanced search

Quick links